Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Issues / 2017 / Mar / Business in Brief
Business and Entrepreneurship Professional Development

Business in Brief

JNJ completes AMO purchase, new CMO for Glaukos and more…

By Ruth Steer 3/2/2017 1 min read

Share

  • Johnson & Johnson has completed its acquisition of Abbot Medical Optics, with the newly combined organization taking the brand name Johnson and Johnson Vision (J&J Vision).

  • Johnson & Johnson has completed its acquisition of Abbot Medical Optics, with the newly combined organization taking the brand name Johnson and Johnson Vision (J&J Vision).
  • L. Jay Katz, director of the glaucoma service at Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University, has been appointed chief medical officer of Glaukos.
  • Regenxbio has announced that the investigational new drug (IND) application for a Phase I trial of its wet AMD drug, RCX-314, is now active. Patient enrolment in the multicenter, open-label, multiple cohort dose escalation trial is expected to begin in Q2/Q3 of this year.
  • Shire has revealed revenue of $54 million from their dry eye drug, Xiidra (lifitegrast), which launched in the USA in August 2016. Shire also announced that it has filed a New Drug Submission (NDS) with Health Canada for the marketing authorization of lifitegrast for the treatment of dry eye in adults.
  • Carl Zeiss Meditec has received FDA approval of a Zeiss VisuMax software update, allowing US surgeons to perform SMILE for the correction of myopia.
  • Bausch + Lomb and Nicox have resubmitted a New Drug Application to the FDA for approval of latanoprostene bunod ophthalmic solution. If approved, the single-agent eyedrop for patients with glaucoma would be the first nitric-oxide donating prostaglandin F2α analog for ophthalmic use.
  • EyeGate has entered into a licensing agreement with Valeant to allow one of Valeant’s subsidiaries worldwide commercial and manufacturing rights to the candidate EGP-437 combination product for post-operative pain and inflammation in ocular surgery patients.
  • The Centers for Medicare and Medicaid Services (CMS) has announced that it will be providing up to $100 million of funding to improve education about the Quality Payment Program. The money will be awarded over the next five years to community-based organizations to provide training and educational resources on the program to small and rural practices across the USA.
  • According to a press release from Ocular Therapeutix, the FDA has accepted a new drug application resubmission for its dexamethasone insert, Dextenza.

About the Author(s)

Ruth Steer

More Articles by Ruth Steer

Related Content

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: